Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
7851172
Publication Date
12-14-2010
Abstract
A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
11/459,793
Filing Date
07/25/2006
Recommended Citation
Lovell, Mark A. and Lynn, Bert C., "Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease" (2010). Chemistry Faculty Patents. 7.
https://uknowledge.uky.edu/chemistry_patents/7
